SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Bionomics Limited BNOX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • AU • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Bionomics Limited (BNOX) is a Biotechnology company in the Healthcare sector, currently trading at $0.25. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is BNOX = $6 (+2270.6% upside).

Net income is $370M (loss), growing at -24099.8%/yr. Net profit margin is 0% (thin). Gross margin is -57291.2% (-54650.8 pp trend).

Balance sheet: total debt is $116M against $19.0B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 3.56 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $28.6B.

Analyst outlook: 4 / 4 analysts rate BNOX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$6.00

▲ 2270.6% Upside

Average Price Target

The 12-month price target for Bionomics Limited is $6.00.

BNOX SharesGrow Score Overview

79/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 0/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BNOX

BNOX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $6, implying +2270.6% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BNOX: -95.8%/yr revenue is, -24099.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet BNOX: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 3.56 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

Analyst outlook: 4 / 4 analysts rate BNOX as buy (100%). Analyst consensus target is $6 (+2270.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.2421-16.32

Volume906.4K

Avg Volume (30D)881.89K

Market Cap$4.95M

Beta (1Y)-0.07

Share Statistics

EPS (TTM)-41.40

Shares Outstanding$90.16K

IPO Date2021-12-16

Employees8

CEOSpyridon Papapetropoulos

Financial Highlights & Ratios

EBITDA$-1.13B

Net Income$-369.63M

Operating Income$-1.13B

Total Cash$14.21B

Total Debt$116.31M

Net Debt$-14.09B

Total Assets$28.59B

Price / Earnings (P/E)-0

Analyst Forecast

1Y Price Target$6.00

Target High$6.00

Target Low$6.00

Upside+2,270.6%

Rating ConsensusBuy

Analysts Covering4

Buy 100% Hold 0% Sell 0%

Company Info

CountryAU

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS09063M2052

Price Chart

BNOX

Bionomics Limited ↗ · NASDAQ Global Market

Healthcare • Biotechnology

0.24 52WK RANGE 16.32

People Also View

Miromatrix Medical Inc.

AN2 Therapeutics, Inc.

Aerovate Therapeutics, Inc.

PMV Pharmaceuticals, Inc.

Acrivon Therapeutics, Inc. Common Stock

Anebulo Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message